Healthcare Industry News: colposcopy
News Release - January 17, 2008
MonoGen Announces Addition of Juan Felix, MD as Medical DirectorCHICAGO, ILLINOIS--(Healthcare Sales & Marketing Network)--Jan 17, 2008 -- MonoGen, Inc., ("Corporation")(Toronto:MOG.TO ) is pleased to announce that Juan Felix, MD, has joined their management team as Medical Director. Dr. Felix is a board certified cytopathologist and is Professor of Clinical Pathology & Obstetrics & Gynecology at Keck School of Medicine, University of Southern California. Also, since 1994, Dr. Felix has served as Director of Pathology and Molecular Pathology at Los Angeles County-USC Women's and Children's Hospital.
Dr. Felix's depth of academic research and clinical experience in cervical cancer, HPV and other GYN malignancies, along with his appointments in OB/GYN, surgical, anatomic and molecular pathology, has resulted in nearly 80 peer-reviewed articles that he has authored or co-authored and fit perfectly with MonoGen's commercial strategy.
In addition to his membership in professional societies dedicated to research and education in gynecologic oncology and clinical pathology, Dr. Felix has been an active participant in the development of the American Society of colposcopy and Cervical Pathology (ASCCP) Clinical Practice Guidelines, of which the ASCCP recently released its landmark report, Consensus Guidelines for the Management of Cytological Abnormalities and Cervical Intraepithelial Neoplasia. Those consensus guidelines influence clinical and laboratory practice nationwide.
Dr. Felix also brings regulatory experience as a member of the FDA Hematology and Pathology Devices Committee since 1997. He will retain his position at USC while serving in this position at MonoGen.
Ted S. Geiselman, President and CEO of MonoGen states, "With Dr. Felix, we get a proven cytopathology researcher, author and practitioner who knows our market extremely well. He will be a critical asset for MonoGen as we commercialize the MonoPrep system as well as to give input on future products for both GYN and non-GYN cytology."
Dr. Felix added," I am thrilled to be joining such an exciting company and opportunity as MonoGen. Their current product offering and future product concepts will be of significant value to the cytopathology community."
With operational headquarters in the United States (Greater Chicago area), MonoGen is a medical diagnostics company developing fully automated devices for anatomic and molecular pathology laboratories. MonoGen's initial product, the MonoPrep Processor, has been designed to automate processes performed by these laboratories to reduce their costs, increase throughput, and improve the quality and consistency of results.
To the extent any statements made in this press release contain information that is not historical; these statements are essentially forward-looking in nature and are subject to risks and uncertainties. Statements preceded by the words believe, expect, anticipate, plan, intend, continue, estimate, may, will, and similar expressions are forward-looking statements.
Forward-looking statements are based on our beliefs and assumptions based on information available at the time the assumption was made. Forward-looking statements relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, new services, market forces, commitments and technological developments, relating to MonoGen USA and us. By its nature, such forward-looking information is subject to various risks and uncertainties which could cause our actual results and experience to differ materially from the anticipated results or other expectations expressed. Those risks and uncertainties include, but are not limited to, our ability to raise additional capital, our ability to execute our business plan while maintaining at all times our various regulatory approvals, the performance of our strategic partners in the commercialization of our products in the marketplace and the competitive response from existing and potential competitors. Readers are cautioned not to place undue reliance on this forward-looking information, which is given as of the date it is expressed in this document, and we undertake no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.